康方生物今日盘中大涨5.01%，引起了市场的广泛关注。
消息面上，此次上涨主要源于市场对前期超跌的重新评估。此前，公司海外合作伙伴Summit Therapeutics公布了依沃西单抗全球三期临床试验Harmoni-3的中期分析结果，其鳞状非小细胞肺癌队列未达到预设的统计学显著性，导致Summit股价大跌，康方生物股价也随之出现补跌，连续两个交易日累计下跌超11%。然而，市场情绪逐步消化后认识到，该中期分析未过仅意味着未能提前揭盲，并非临床失败，试验将继续推进至最终分析。
此外，华福证券维持对康方生物的“买入”评级，并通过DCF模型测算其合理股价为206港元，指出当前股价仍存在较大的折价空间。基于对长期价值的重新认识，部分资金开始进行逢低回补操作，推动了股价的显著反弹。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.